The client is receiving antibiotics for a wound infection when their susceptibility results become available. The causative organism is Pseudomonas aeruginosa, which the nurse recognizes as a bacteria with high resistance. Which drug therapy option is most likely to be effective?

Introduction: Pseudomonas aeruginosa is an opportunistic, gram-negative aerobe characterized by intrinsic resistance to many common antimicrobials due to its efflux pumps and low membrane permeability. Treatment requires "anti-pseudomonal" agents, such as specific carbapenems or specialized cephalosporins, which can withstand the organism's diverse beta-lactamase production and successfully penetrate its complex cell wall. A. Amoxicillin is a moderate-spectrum aminopenicillin that is primarily effective against gram-positive cocci and a limited number of gram-negative organisms. It is highly susceptible to beta-lactamases produced by Pseudomonas aeruginosa, rendering it completely ineffective as a therapeutic option for this specific multi-drug resistant bacterial infection. B. Cefazolin is a first-generation cephalosporin that offers excellent coverage against gram-positive organisms and some gram-negative bacteria like E. coli. However, first-generation cephalosporins lack the necessary biochemical structure to resist the defenses of Pseudomonas aeruginosa, which typically requires third or fourth-generation cephalosporins or carbapenems for effective eradication. C. Erythromycin is a macrolide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit, primarily targeting gram-positive and atypical organisms. It possesses virtually no clinically significant activity against Pseudomonas aeruginosa and would be an inappropriate choice for a systemic or deep-tissue wound infection caused by this pathogen. D. Imipenem-cilastatin is a broad-spectrum carbapenem that is highly resistant to most beta-lactamases and is specifically indicated for serious infections caused by Pseudomonas aeruginosa. The cilastatin component prevents the rapid renal metabolism of imipenem, ensuring that therapeutic concentrations of the antibiotic reach the site of the wound infection to exert its bactericidal effect.